M&A Deal Summary |
|
|---|---|
| Date | 2025-11-04 |
| Target | Parse Biosciences |
| Sector | Life Science |
| Buyer(s) | Qiagen N.V |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1984 |
| Sector | Life Science |
| Employees | 5,200 |
| Revenue | 1.5B USD (2019) |
QIAGEN N.V. is a Netherlands holding company publically traded on NASDAQ and Frankfurt Prime Standard. The Company is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular insights. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Qiagen was founded in 1986 and is based in Venlo, the Netherlands.
| DEAL STATS | # |
|---|---|
| Overall | 17 of 17 |
| Sector: Life Science M&A | 8 of 8 |
| Type: Add-on Acquisition M&A Deals | 16 of 16 |
| State: Washington M&A | 1 of 1 |
| Country: United States M&A | 12 of 12 |
| Year: 2025 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-01-09 |
Verogen
San Diego, California, United States Verogen is a developer, manufacturer, and sells forensic genomics products and services, including for next-generation sequencing. Verogen was formed in 2017 and is based in San Diego, California. |
Buy | $150M |
